Targeting CD24 for treatment of ovarian cancer by short hairpin RNA

Cytotherapy

Volumn 11, Issue 5, 2009, Pages 642-652

  Su, Dan ^a   Deng, Hongxin ^b   Zhao, Xia ^a   Zhang, Xi ^b   Chen, Lijuan ^b   Chen, Xiancheng ^a   Li, Zhengyu ^a   Bai, Yu ^a   Wang, Yongsheng ^b   Zhong, Qian ^a   Yi, Tao ^a   Qian, Zhiyong ^b   Wei, Yuquan ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; CD24; Ovarian cancer; RNA interference

Indexed keywords

CD24 ANTIGEN; CD31 ANTIGEN; CYCLINE; PLASMID VECTOR; PROPIDIUM IODIDE; SHORT HAIRPIN RNA; TETRAZOLIUM BLUE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; STAINING; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD24; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING;

EID: 70849134276     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240902878308     Document Type: Article

References (45)

1. Cannistra SA. C ancer of the ovary. N Engl J Med 1993; 329: 1550-1559
2. Jemal A, M urray T, Ward E, S amuels A, T iwari RC, G hafoor A, et al. Cancer statistics 2005. CACancer J Clin 2005; 55: 10-30.
3. Kristiansen G, Winzer KJ, Mayordomo E, B ellach J, S chluns K, Denkert C, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003; 9: 4906-4913
4. Weichert W, D enkert C, B urkhardt M, G ansukh T, Bellach J, Altevogt P, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005; 11: 6574-6581
5. Kristiansen G, P ilarsky C, W issmann C, K aiser S, B ruemmendorf T, Roepcke S, et al. Expression profi ling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005; 205: 359-376
6. Schabath H, Runz S, Joumaa S, A ltevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006; 119: 314-325
7. Friederichs J, Z eller Y, H afezi-Moghadam A, G rone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000; 60: 6714-6722
8. Baumann P, C remers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005; 65: 10783-10793
9. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002; 161: 1215-1221
10. Taguchi T, K iyokawa N, Mimori K, Suzuki T, S ekino T, Nakajima H. Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells. J Immunol 2003; 170: 252-260
11. Smith SC, O xford G, Wu Z, N itz MD, Conaway M, Frierson HF, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006; 66: 1917-1922
12. Yu J-Y, D eRuiter SL, T urner DL. R NA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 6047-6052
13. Nabel GJ, N abel EG, Yang Z-Y, F ox BA, P lautz G, G ao X, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11311
14. Wu Y, L i ZY, Z hao X, K an B, W ei YQ. I nhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2. Hum Gene Ther 2006; 17: 941-948
15. Li Z, Z hao X, Bai S, W ang Z, C hen L, Wei Y, H uang C. Proteomics identifi cation of cyclophilin A as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics 2008; 7: 1810-1823
16. Fehrmann RS, Li XY, v an der Zee AG, de Jong S, Te Meerman GJ, de Vries EG, Crijns AP. Profi ling studies in ovarian cancer: a review. Oncologist 2007; 12: 960-966
17. Cross D, B urmester JK. G ene therapy for cancer treatment: past, present and future. Clin Med Res 2006; 4: 218-227
18. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn Jr, Ruppert M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997; 89: 3385-3395 (Pubitemid 27229826)
19. Pirruccello SJ, L ang MS. D ifferential expression of CD24-related epitopes in mycosis fungoides/Sezary syndrome. a potential marker for circulating Sezary cells. Blood 1990; 76: 2343-2347
20. Droz D, Zachar D, Charbit L, Gogusev J, Chretein Y, Iris L. Expression of the human nephron differentiation molecules in renal cell carcinoma. Am J Pathol 1990; 137: 895-905. (Pubitemid 20337804)
21. Jackson D, W aibel R, W eber E, B ell J, S tahel RA. C D24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 1992; 52: 5264-5270
22. Fukushima T, T ezuka T, S himomura T, N akano S, K ataoka H. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 2007; 282: 18634-18644
23. Chou Y-Y, Jeng Y-M, Lee T-T, Hu F-C, K ao H-L, L in W-C, et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 2007; 14: 2748-2758
24. Huang L-R, H su H-C. C loning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995; 55: 4717-4721
25. Gonzalez HE, Gujrati M, F rederick M, H enderson Y, Arumugam J, Spring PW, et al. Identifi cation of 9 genes differentially expressed in head and neck squamous cell carcinoma. Arch Otolaryngol 2003; 129: 754-759
26. Yokoyama M, Nishi Y, Y oshii J, Okubo K, Matsubara K. Identifi cation and cloning of neuroblastoma-specifi c and nerve tissue-specifi c genes through compiled expression profi les. DNA Res 1996; 3: 311-320
27. Szotek PP, P ieretti-Vanmarcke R, M asiakos PT, D inulescu DM, Connolly D, et al. Ovarian cancer side population defi nes cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-11159
28. Smith J, K ontermann RE, Embleton J, K umar S. A ntibody phage display technologies with special reference to angiogenesis. FASEB J 2005; 19: 331-341
29. Bodey B, B odey B Jr, S iegel SE, Kaiser HE. G enetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specifi c delivery of chemotherapeutic agents. Curr Pharm Des 2000; 6: 261-276
30. Bertrand JR, P ottier M, V ekris A, O polon P, M aksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296: 1000-1004
31. Ma HT, O n KF, T sang YH, P oon RYC. A n inducible system for expression and validation of the specifi city of short hairpin RNA in mammalian cells. Nucleic Acids Res 2007; 35: e22.
32. Koller E, P ropp S, M urray H, L ima W, B hat B, P rakash TP, et al. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res 2006; 34: 4467-4476
33. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378
34. Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses: strike and counterstrike. Nat Biotechnol 2007; 25: 1435-1443
35. Drummond DC, Meyer O, Hong K, K irpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemo-therapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691-743.
36. Yuan F, L eunig M, Huang SK, B erk DA, P apahadjopoulos D, Jam RK. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54: 3352-3356
37. Halder J, K amat AA, Landen CN, H an L, L utgendorf SK, Lin YG, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006; 12: 4916-4924
38. Lin X, Chen X, W ei Y, Z hao J, Fan L, W en Y, et al. Effi cient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 2007; 104: 540-546
39. Harrington KJ, M ohammadtaghi S, U ster PS, G lass D, Peters AM, Vile RG, Stewart JS. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7: 243-254
40. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic infl ammation in mice. J Clin Invest 1998; 101: 1401-1413
41. Sagiv E, S tarr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008; 68: 2803-2812
42. Ghobrial IM, W itzig TE, A djei AA. T argeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-194
43. Sellers WR, F isher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999; 104: 1655-1661
44. Hobbs SK, M onsky WL, Y uan F, R oberts WG, G riffi th L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95: 4607-4612
45. Rundhaug JE. M atrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 2003; 9: 551-554